Read Time:38 Second
Shares of Pliant Therapeutics Inc. jumped 41.6% in premarket trading on Monday after the company shared positive data from a Phase 2a clinical trial for its experimental idiopathic pulmonary fibrosis treatment. The study, which so far has evaluated 40-, 80-, and 160-milligram doses, met the primary and secondary endpoints. Pliant said Monday it also plans to test a 320-milligram dose of the therapy in the Phase 2 trial, with plans to share 12-week data from that cohort early next year. Pliant’s stock is down 34.2% this year, while the broader S&P 500 has declined 18.2%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
